|D000787||Angina Pectoris NIH||1.00|
|D054143||Heart Failure, Systolic NIH||1.00|
|D054058||Acute Coronary Syndrome NIH||0.50|
|HP:0001681||Angina pectoris HPO||1.00|
|HP:0001677||Coronary artery atherosclerosis HPO||0.50|
|HP:0001635||Congestive heart failure HPO||0.35|
There is one clinical trial.
Healthcare workers in Wisconsin caring for critically ill COVID-19 patients will be most impacted by the proposed project. Evidence has shown that the SARS-CoV-2 novel coronavirus is easily transmissable through close contact between individuals, especially during aerosol-generating procedures such as intubation of patients. The intervention proposed in this study (nasal and oral decontamination with povidone-iodine and chlorhexidine, respectively) presents an opportunity for a safe, effective, and feasible treatment to decontaminate the primary entry points for SARS-CoV-2. As such, the intervention to be studied in this project may protect healthcare workers by preventing transmission of SARS-CoV-2 from patients to healthcare workers, and thus reducing the incidence of COVID-19 in these healthcare workers.
Description: Participants will be monitored for positive COVID-19 test results during this trialMeasure: Number of Participants with COVID-19 diagnosis Time: 8 weeks
Description: Viral load will be measured as a continuous outcome for each participant (three times per week) throughout this trial.Measure: SARS-Cov-2 Viral Load Time: 8 weeks
Description: Assessment of fidelity (as measured by percentage of compliance) to the treatment regimen will be measured by participants' reporting of intervention doses take through a daily treatment diary.Measure: Fidelity of the treatment regimen Time: 8 weeks
Description: A survey asking subjects to rank several factors that contribute to overall feasibility of use will be given pre- and post-intervention treatment.Measure: Feasibility of the treatment regimen Time: 2 weeks total: 1 week (pre-intervention) and 1 week after completion of intervention (post-intervention)
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports